# EDGAR Filing Document

**Accession Number:** 0001853723
**File Stem:** 0001193125-26-217656
**Filing Date:** 2026-5
**Character Count:** 16528
**Document Hash:** 1f0138e592025b05a9d7164762b93f6f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-217656.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001193125-26-217656

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260511

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** George Simeon
- **CENTRAL INDEX KEY:** 0001595117

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43270
- **FILM NUMBER:** 26965344

**MAIL ADDRESS:**
- **STREET 1:** C/O SR ONE CAPITAL MANAGEMENT, LP
- **STREET 2:** 929 MAIN STREET, SUITE 200
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** SR ONE CAPITAL MANAGEMENT, LLC
- **CENTRAL INDEX KEY:** 0001853723

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43270
- **FILM NUMBER:** 26965345

**BUSINESS ADDRESS:**
- **STREET 1:** 929 MAIN STREET
- **STREET 2:** SUITE 200
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** (410) 800-7503

**MAIL ADDRESS:**
- **STREET 1:** 929 MAIN STREET
- **STREET 2:** SUITE 200
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Odyssey Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001882782
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863384382
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 51 SLEEPER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** (212) 841-1000

**MAIL ADDRESS:**
- **STREET 1:** 51 SLEEPER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>SR ONE CAPITAL MANAGEMENT, LLC<br><sub>(Last) (First) (Middle)</sub><br>929 MAIN STREET<br>SUITE 200<br><sub>(Street)</sub><br>REDWOOD CITY, CA 94063<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Odyssey Therapeutics, Inc. [ ODTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>George Simeon<br><sub>(Last) (First) (Middle)</sub><br>929 MAIN STREET<br>SUITE 200<br><sub>(Street)</sub><br>REDWOOD CITY, CA 94063<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Odyssey Therapeutics, Inc. [ ODTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-11 |  | C |  | 474048 | A | <sup>(1)</sup> | 474048 | I | See Note 2<sup>(2)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 139366 | A | <sup>(3)</sup> | 613414 | I | See Note 2<sup>(2)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 59692 | A | <sup>(4)</sup> | 673106 | I | See Note 2<sup>(2)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 61762 | A | <sup>(5)</sup> | 734868 | I | See Note 2<sup>(2)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 683817 | A | <sup>(6)</sup> | 1418685 | I | See Note 2<sup>(2)</sup> |
| Common Stock | 2026-05-11 |  | X |  | 191541 | A | <sup>(7)</sup> | 1610226 | I | See Note 2<sup>(2)</sup> |
| Common Stock | 2026-05-11 |  | S<sup>(7)</sup> |  | 1065<sup>(8)</sup> | D | $18.00 | 1609161 | I | See Note 2<sup>(2)</sup> |
| Common Stock | 2026-05-11 |  | P |  | 222222 | A | $18.00 | 1831383 | I | See Note 2<sup>(2)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 118512 | A | <sup>(1)</sup> | 118512 | I | See Note 9<sup>(9)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 255823 | A | <sup>(4)</sup> | 374335 | I | See Note 9<sup>(9)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 204658 | A | <sup>(4)</sup> | 204658 | I | See Note 10<sup>(10)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 20582 | A | <sup>(5)</sup> | 225240 | I | See Note 10<sup>(10)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 166168 | A | <sup>(6)</sup> | 391408 | I | See Note 10<sup>(10)</sup> |
| Common Stock | 2026-05-11 |  | X |  | 49850 | A | <sup>(7)</sup> | 441258 | I | See Note 10<sup>(10)</sup> |
| Common Stock | 2026-05-11 |  | S<sup>(7)</sup> |  | 277<sup>(11)</sup> | D | $18 | 440981 | I | See Note 10<sup>(10)</sup> |
| Common Stock | 2026-05-11 |  | P |  | 133333 | A | $18 | 574314 | I | See Note 10<sup>(10)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 463106 | A | <sup>(5)</sup> | 463106 | I | See Note 12<sup>(12)</sup> |
| Common Stock | 2026-05-11 |  | C |  | 273527 | A | <sup>(6)</sup> | 736633 | I | See Note 12<sup>(12)</sup> |
| Common Stock | 2026-05-11 |  | X |  | 78656 | A | <sup>(7)</sup> | 815289 | I | See Note 12<sup>(12)</sup> |
| Common Stock | 2026-05-11 |  | S<sup>(7)</sup> |  | 438<sup>(13)</sup> | D | $18 | 814851 | I | See Note 12<sup>(12)</sup> |
| Common Stock | 2026-05-11 |  | P |  | 200000 | A | $18 | 1014851 | I | See Note 12<sup>(12)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series A Convertible Preferred Stock | <sup>(1)</sup> | 2026-05-11 |  | C |  |  | 4606320 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 474048 | <sup>(1)</sup> | 0 | I | See Note 2<sup>(2)</sup> |
| Series A-2 Convertible Preferred Stock | <sup>(3)</sup> | 2026-05-11 |  | C |  |  | 1299842 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 139366 | <sup>(3)</sup> | 0 | I | See Note 2<sup>(2)</sup> |
| Series B Convertible Preferred Stock | <sup>(4)</sup> | 2026-05-11 |  | C |  |  | 544162 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 59692 | <sup>(4)</sup> | 0 | I | See Note 2<sup>(2)</sup> |
| Series C Convertible Preferred Stock | <sup>(5)</sup> | 2026-05-11 |  | C |  |  | 600142 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 61762 | <sup>(5)</sup> | 0 | I | See Note 2<sup>(2)</sup> |
| Series D Convertible Preferred Stock | <sup>(6)</sup> | 2026-05-11 |  | C |  |  | 6644650 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 683817 | <sup>(6)</sup> | 0 | I | See Note 2<sup>(2)</sup> |
| Series D Warrants (Right to Buy) | $0.10 | 2026-05-11 |  | X |  |  | 1861211 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 191541 | <sup>(7)</sup> | 0 | I | See Note 2<sup>(2)</sup> |
| Series A Convertible Preferred Stock | <sup>(1)</sup> | 2026-05-11 |  | C |  |  | 1151580 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 118512 | <sup>(1)</sup> | 0 | I | See Note 9<sup>(9)</sup> |
| Series B Convertible Preferred Stock | <sup>(4)</sup> | 2026-05-11 |  | C |  |  | 2374981 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 255823 | <sup>(4)</sup> | 0 | I | See Note 9<sup>(9)</sup> |
| Series B Convertible Preferred Stock | <sup>(4)</sup> | 2026-05-11 |  | C |  |  | 1899984 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 204658 | <sup>(4)</sup> | 0 | I | See Note 10<sup>(10)</sup> |
| Series C Convertible Preferred Stock | <sup>(5)</sup> | 2026-05-11 |  | C |  |  | 200000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 20582 | <sup>(5)</sup> | 0 | I | See Note 10<sup>(10)</sup> |
| Series D Convertible Preferred Stock | <sup>(6)</sup> | 2026-05-11 |  | C |  |  | 1614650 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 166168 | <sup>(6)</sup> | 0 | I | See Note 10<sup>(10)</sup> |
| Series D Warrants (Right to Buy) | $0.10 | 2026-05-11 |  | X |  |  | 484395 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 49850 | <sup>(7)</sup> | 0 | I | See Note 10<sup>(10)</sup> |
| Series C Convertible Preferred Stock | <sup>(5)</sup> | 2026-05-11 |  | C |  |  | 4500000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 463106 | <sup>(5)</sup> | 0 | I | See Note 12<sup>(12)</sup> |
| Series D Convertible Preferred Stock | <sup>(6)</sup> | 2026-05-11 |  | C |  |  | 2657860 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 273527 | <sup>(6)</sup> | 0 | I | See Note 12<sup>(12)</sup> |
| Series D Warrants (Right to Buy) | $0.10 | 2026-05-11 |  | X |  |  | 764312 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 78656 | $0 | 0 | I | See Note 12<sup>(12)</sup> |

---

### Footnotes:

(1) The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.

(2) The securities are directly held by SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"). SR One Capital Partners I, LP ("SR One Partners I") is the sole general partner of SR One Fund I Aggregator, and SR One Capital Management, LLC ("SR One Capital Management") is the sole general partner of SR One Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Capital Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

(3) The Series A-2 Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.3268 basis for no additional consideration.

(4) The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.

(5) The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.

(6) The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.

(7) The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.

(8) Pursuant to the terms of the warrants, the Issuer withheld 1,065 warrant shares to pay the exercise price in connection with the net exercise.

(9) The securities are directly held by SR One Co-Invest IV, LLC ("SR One Co-Invest IV"). SR One Co-Invest IV Manager, LLC ("SR One Co-Invest Manager") is the managing member of SR One-Co-Invest IV, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

(10) The securities are directly held by SR One Co-Invest IV-A, LLC ("SR One Co-Invest IV-A"). SR One Co-Invest IV Manager is the managing member of SR One-Co-Invest IV-A, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

(11) Pursuant to the terms of the warrants, the Issuer withheld 277 warrant shares to pay the exercise price in connection with the net exercise.

(12) The reported securities are held directly by AMZL, LP ("AMZL"). SR One Capital SMA Partners, LP ("SR One SMA Partners") is the general partner of AMZL, and SR One Capital Management is the general partner of SR One SMA Partners. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One SMA Partners, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

(13) Pursuant to the terms of the warrants, the Issuer withheld 438 warrant shares to pay the exercise price in connection with the net exercise.

**Signature:** /s/ Sasha Keough, attorney-in-fact for SR One Capital Management, LLC  
**Date:** 2026-05-11

**Signature:** /s/ Sasha Keough, attorney-in-fact for Simeon George  
**Date:** 2026-05-11

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**